BioCrossroads (Indianapolis), the Indiana life sciences trade association, is co-sponsoring with the Indiana Economic Development Corp. a visit by a delegation of business leaders from India late this month.
The delegation will include industry representatives from biotechnology, information technology, infrastructure, medical and hospital facilities, and financial services companies in India.
In addition to facilitating one-on-one meetings with executives of the visiting companies, the IEDC will host a seminar on Feb. 27 on the subject, “India as a Strategic Partner in Trade and Business - A New Horizon.” That session will take place at the Omni Severin Hotel in Indianapolis.
Calypte Biomedical not in Amex compliance
Calypte Biomedical (Lake Oswego, Oregon) said that on Feb. 2, it received notice from the American Stock Exchange indicating that the company no longer complies with the exchange's continued listing standards set forth in the exchange's Company Guide. Specifically, the exchange noted that the company has shareholders' equity of less than $2 million and losses from continuing operations and/or net losses in two out of its three most recent fiscal years.
Amex said its financial condition has become so impaired that it appears questionable, in the opinion of the exchange, as to whether the company will be able to continue operations and/or meet its obligations as they mature. As a result of this lack of compliance, the exchange's staff has determined to initiate delisting proceedings with respect to the company's common stock.
Calypte, a maker of diagnostic testing products, has until Feb. 10 to request an appeal.